Market Research Report
Pneumonia Drug Development Pipeline Review, 2017
|Published by||GlobalData||Product code||564940|
|Published||Content info||123 Pages
Delivery time: 1-2 business days
|Pneumonia Drug Development Pipeline Review, 2017|
|Published: September 26, 2017||Content info: 123 Pages||
Community acquired pneumonia refers to pneumonia contracted by a person who has had little contact with the healthcare system. There are a total of 20 products in development for this indication, by 17 companies. Key companies operating in this pipeline space include TaiGen Biotechnology and Merck.
Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted, usually caused by a bacterial infection. There are a total of 39 products in development for this indication, by 29 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, Wockhardt, AstraZeneca and Merck.
Finally, Ventilator-associated pneumonia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 34 products in development for this indication, by 27 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, AstraZeneca, Merck and Polyphor.
The most common targets within community acquired pneumonia are DNA gyrase, DNA topoisomerase and ribosomal RNA, common targets of antibiotics. Hospital acquired and ventilator associated pneumonia share many of the same targets and are most frequently targeted towards beta lactamase and ribosomal RNA, also common targets of antibiotic treatments and closely reflecting the current treatment landscape of these diseases.
The report,"Pneumonia Drug Development Pipeline Review, 2017" provides an overview of the pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.